



Drug Coverage Decision for BC PharmaCare

About PharmaCare

BC PharmaCare is a publicly funded drug plan that helps B.C. residents pay for most prescription drugs and pharmacy services, and some medical devices and supplies.

Details of Drug Reviewed

Drug	risankizumab
Brand name	Skyrizi®
Dosage forms	600 mg intravenous infusion and 360 mg subcutaneous injection
Manufacturer	AbbVie Corporation
Submission type	New Submission
Indication reviewed	For the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response, intolerance, or demonstrated dependence to corticosteroids; or an inadequate response, intolerance, or loss of response to immunomodulators or biologic therapies.
Canada's Drug Agency (CDA-AMC) Reimbursement Reviews (CRR)	CRR recommended: to Reimburse with clinical criteria and/or conditions. Visit the CRR website for more details .
Provincial Review	The Drug Benefit Council (DBC) screens drug submissions under review by the CRR to determine whether a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry of Health's (the Ministry's) drug coverage decision will be based on the Canadian Drug Expert Committee (CDEC) recommendation and an internal review only. The DBC screened risankizumab for Crohn's disease in January 2023. The DBC advised that, because risankizumab is similar to other drugs used for the treatment of Crohn's disease, the Ministry may accept the CDEC's recommendation for risankizumab.
Drug Coverage Decision	Limited Coverage benefit. Special Authority criteria is available here.

Date	May 30, 2024
Reasons	<p>Drug coverage decision is consistent with the CDEC recommendation.</p> <ul style="list-style-type: none"> • Risankizumab demonstrated some advantages over placebo with respect to efficacy and safety in people with moderately to severely active Crohn's disease. • There was insufficient evidence regarding the relative efficacy and safety of risankizumab as compared to other biologics currently reimbursed for the treatment of adult patients with moderately to severely active Crohn's disease. • The Ministry participated in the pan-Canadian Pharmaceutical Alliance negotiations with the manufacturer which were able to address the concerns identified by the CDEC with respect to the cost-effectiveness and value for money.
Other Information	None

The drug review process in B.C.

A manufacturer submits a request to the Ministry of Health (the Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry by considering:

- whether the drug is safe and effective
- advice from a national group called [Canada's Drug Agency](#) (CDA-AMC)
- what the drug costs and whether funding it provides good value to the province
- ethical considerations of covering and not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by taking into account:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug

Visit [BC PharmaCare](#) and [Drug reviews](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.